Image via MedCity News
Last updated
UCB: Ma Activity
UCB completed $2B acquisition of Candid Therapeutics, acquiring two clinical-stage T cell engagers for autoimmune disorders
Source: MedCity News
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: Against a Talent Market Index of 107.9 (Hot) (up 2.4 month-on-month), Oceania is at easing (-7.9pts) on signal share.
UCB: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 25 tracked companies; 0.2% of MitchelLake's EMEA signal flow; 3 tracked across 17 days.
MitchelLake in this thematic
Also at UCB →
More signals across Biotech & Pharma
Ma Activity · Oceania
Teva Pharmaceuticals →Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Partnership · Oceania
AusBiotech →AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Intelligence powered by Autonodal ↗